Literature DB >> 24740531

Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models.

S Stegemann1, J-P Baeyens, R Becker, M Maio, M Bresciani, T Shreeves, F Ecker, M Gogol.   

Abstract

Drugs represent the most common intervention strategy for managing acute and chronic medical conditions. In light of demographic change and the increasing age of patients, the classic model of drug research and development by the pharmaceutical industry and drug prescription by physicians is reaching its limits. Different stakeholders, e.g. industry, regulatory authorities, health insurance systems, physicians etc., have at least partially differing interests regarding the process of healthcare provision. The primary responsibility for the correct handling of medication and adherence to treatment schedules lies with the recipient of a drug-based therapy, i.e. the patient. It is thus necessary to interactively involve elderly patients, as well as the other stakeholders, in the development of medication and medication application devices, and in clinical trials. This approach will provide the basis for developing a strategy that better meets patients' needs, thus resulting in improved adherence to treatment schedules and better therapeutic outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24740531     DOI: 10.1007/s00391-014-0647-4

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  8 in total

1.  Adverse drug events in high risk older outpatients.

Authors:  J T Hanlon; K E Schmader; M J Koronkowski; M Weinberger; P B Landsman; G P Samsa; I K Lewis
Journal:  J Am Geriatr Soc       Date:  1997-08       Impact factor: 5.562

Review 2.  Geriatric drug therapy: neglecting the inevitable majority.

Authors:  Sven Stegemann; Felix Ecker; Mario Maio; Peter Kraahs; Rainer Wohlfart; Joerg Breitkreutz; Andreas Zimmer; Daniel Bar-Shalom; Patrick Hettrich; Bianca Broegmann
Journal:  Ageing Res Rev       Date:  2010-05-15       Impact factor: 10.895

3.  Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy.

Authors:  Francesca Cerreta; Hans-Georg Eichler; Guido Rasi
Journal:  N Engl J Med       Date:  2012-11-22       Impact factor: 91.245

4.  Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study.

Authors:  C C Klaver; R C Wolfs; J R Vingerling; A Hofman; P T de Jong
Journal:  Arch Ophthalmol       Date:  1998-05

5.  Functional ability of patients to manage medication packaging: a survey of geriatric inpatients.

Authors:  P A Atkin; T P Finnegan; S J Ogle; G M Shenfield
Journal:  Age Ageing       Date:  1994-03       Impact factor: 10.668

Review 6.  Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy.

Authors:  S Stegemann; M Gosch; J Breitkreutz
Journal:  Int J Pharm       Date:  2012-04-15       Impact factor: 5.875

Review 7.  Medication non-adherence in the elderly: how big is the problem?

Authors:  Carmel M Hughes
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Interventions for helping patients to follow prescriptions for medications.

Authors:  R B Haynes; H McDonald; A X Garg; P Montague
Journal:  Cochrane Database Syst Rev       Date:  2002
  8 in total
  1 in total

Review 1.  Developing patient-centric medicines for older people: Reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population.

Authors:  Diana A van Riet-Nales; Katarina Sundberg; Anthonius de Boer; Blanka Hirschlérova
Journal:  Br J Clin Pharmacol       Date:  2020-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.